Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting
Results support AGTC's clinical development strategies in both conditions Phase 1/2 trial in patients with achromatopsia due to CNGB3 mutations is currently enrolling patients; Phase 1/2 trial in patients with CNGA3-related achromatopsia is scheduling patients for enrollment WASHINGTON, May 11,
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis (XLRS) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Results expected to enhance development of AGTC's XLRS gene therapy candidate; Phase 1/2 clinical trial currently enrolling patients at multiple locations across the United States
View HTML
Toggle Summary AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 10, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it
View HTML
Toggle Summary AGTC to Present at the 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Present at the 29th Annual ROTH Conference on March 14, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Selected as Top Company in the University of Florida's 2017 Gator100
Award Recognizes Fastest Growing Global Businesses Owned or Led by UF Graduates
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2016
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 8, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it
View HTML
Toggle Summary AGTC and Bionic Sight Announce Strategic Collaboration to Develop an Optogenetic Therapy and Device for Visual Deficits and Blindness
Innovative approach will combine AGTC's gene therapy expertise with Bionic Sight's neuro-prosthetic device to potentially restore retinal function
View HTML
Visionary science for life changing cures.